tegafur has been researched along with Bile Duct Neoplasms in 64 studies
Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging." | 9.22 | Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. ( Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ, 2016) |
| "The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy." | 9.14 | A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. ( Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Sato, T; Yamaguchi, T; Yamao, K, 2009) |
| "The aim of this study was to investigate the prognostic significance of HuR in cholangiocarcinoma patients who received adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection." | 7.88 | Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. ( Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K, 2018) |
| "We report curative resection of an advanced intrahepatic cholangiocarcinoma that responded well to combined S-1 and gemcitabine chemotherapy(GS therapy)." | 7.83 | [Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy]. ( Fukuda, S; Kuga, Y; Moriya, T; Nishida, T, 2016) |
| "We experienced a case of good response in acute respiratory distress syndrome (ARDS) treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma." | 7.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Hilar cholangiocarcinoma is an uncommon cancer and its overall incidence is increasing." | 6.79 | Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. ( Choi, HJ; Choi, JH; Eum, JB; Jang, JW; Kim, HJ; Kim, MH; Lee, JB; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, SE; Seo, DW, 2014) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Advanced intrahepatic cholangiocarcinoma (ICC) is a highly challenging malignancy characterized by rapid progression and poor prognosis." | 5.56 | Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. ( Cao, L; Li, S; Liu, J; Wang, C, 2020) |
| "Simvastatin has inhibitory effects on cancers." | 5.39 | Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism. ( Cai, JP; Chen, W; Hao, XY; Hou, X; Liang, LJ; Yin, XY, 2013) |
| "Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging." | 5.22 | Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. ( Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ, 2016) |
| "The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy." | 5.14 | A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. ( Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Sato, T; Yamaguchi, T; Yamao, K, 2009) |
| "The aim of this study was to investigate the prognostic significance of HuR in cholangiocarcinoma patients who received adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection." | 3.88 | Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. ( Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K, 2018) |
| "We report curative resection of an advanced intrahepatic cholangiocarcinoma that responded well to combined S-1 and gemcitabine chemotherapy(GS therapy)." | 3.83 | [Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy]. ( Fukuda, S; Kuga, Y; Moriya, T; Nishida, T, 2016) |
| "We experienced a case of good response in acute respiratory distress syndrome (ARDS) treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma." | 3.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT." | 3.67 | [MQF-FT and MQF-UFT in gallbladder and bile duct cancer]. ( Fukushi, G; Itoh, T; Kimura, M; Kimura, T; Kishibe, T; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y; Tsushima, K, 1988) |
| "Patients with pancreatic cancer commonly suffer from exocrine pancreatic insufficiency, and the ingestion of digestive enzyme supplements may improve absorption." | 2.87 | Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018) |
| "Hilar cholangiocarcinoma is an uncommon cancer and its overall incidence is increasing." | 2.79 | Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. ( Choi, HJ; Choi, JH; Eum, JB; Jang, JW; Kim, HJ; Kim, MH; Lee, JB; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, SE; Seo, DW, 2014) |
| "Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy." | 2.74 | [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Advanced intrahepatic cholangiocarcinoma (ICC) is a highly challenging malignancy characterized by rapid progression and poor prognosis." | 1.56 | Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. ( Cao, L; Li, S; Liu, J; Wang, C, 2020) |
| "In our case, we report a gallbladder cancer with portal vein thrombus." | 1.48 | Gallbladder cancer with tumor thrombus in the portal vein: A case report. ( Bai, XL; Chen, W; Liang, TB; Ma, T; Tu, JJ; Zhang, XZ, 2018) |
| "We encountered a case of resected gastric cancer, which occurred concomitantly with intrahepatic cholangiocarcinoma after S-1 plus cisplatin chemotherapy, in a patient who was previously diagnosed with metastatic liver tumor before treatment." | 1.42 | [A Case of Resected Gastric Cancer Occurring Simultaneously with Intrahepatic Cholangiocarcinoma after S-1 plus Cisplatin Chemotherapy]. ( Danno, K; Fujitani, K; Iwase, K; Kawada, J; Kitagawa, A; Kubota, M; Matsuda, C; Matsuura, N; Miyazaki, S; Motoori, M; Nakatsuka, R; Nishimura, M; Nomura, M; Okumura, Y, 2015) |
| "An abdominal CT demonstrated local recurrence at the hepatoduodenal ligament." | 1.42 | [A Case of Local Recurrence of Bile Duct Cancer Completely Responding to Chemoradiotherapy with S-1]. ( Hishikawa, H; Matsuura, T; Ozaki, T; Saito, T; Sakaguchi, T; Sueyoshi, H; Tanaka, Y; Ueda, A; Yamamichi, K, 2015) |
| "Biliary papillomatosis is rare, and its pathogenic mechanisms are not yet clear." | 1.42 | Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report. ( Cheong, CO; Kim, HK; Kim, KS; Lim, JH; Park, JS; Park, SW, 2015) |
| "The tumor was diagnosed as hepatocellular carcinoma by MRI and CT." | 1.42 | [Six-year survival with recurrent intrahepatic cholangiocarcinoma achieved by simple S-1 administration]. ( Hirose, T; Ishikawa, Y; Kitamura, K; Miki, A; Minami, T; Morioka, H; Nishihira, T; Otani, T; Suzuki, T; Yoshitani, S, 2015) |
| "Treatment for unresectable intrahepatic cholangiocarcinoma (ICC) has not been established." | 1.42 | Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. ( Abei, M; Fukuda, K; Hashimoto, T; Ishikawa, H; Mizumoto, M; Ohkawa, A; Okumura, T; Sakae, T; Sakurai, H; Tsuboi, K, 2015) |
| "Medical records of 133 patients with extrahepatic cholangiocarcinoma who underwent curative resection were reviewed retrospectively." | 1.39 | Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. ( Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K, 2013) |
| "Simvastatin has inhibitory effects on cancers." | 1.39 | Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism. ( Cai, JP; Chen, W; Hao, XY; Hou, X; Liang, LJ; Yin, XY, 2013) |
| "We report a case of bile duct cancer with a positive surgical margin obtaining long-term survival after S-1 monotherapy." | 1.38 | [A case of bile duct cancer with positive surgical margin obtaining long-term survival after S-1 monotherapy]. ( Harada, N; Hayashi, T; Imaizumi, T; Kaji, S; Koike, N; Morishita, K; Suzuki, M; Suzuki, S; Takeo, Y, 2012) |
| "Computed tomography showed nodal recurrence 6 months after surgery." | 1.37 | [A case of long-term survival of a patient with intrahepatic bile duct cancer and early nodal recurrence who responded to S-1 therapy]. ( Kametaka, H; Koyama, T; Makino, H; Seike, K, 2011) |
| "A 60-year-old man with intrahepatic cholangiocarcinoma (ICC) underwent a left hepatectomy." | 1.37 | [A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy]. ( Akagi, K; Dono, K; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Miyake, M; Nagai, K; Shimano, T; Shimizu, J, 2011) |
| "To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present." | 1.36 | [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tanida, T; Umeshita, H; Wada, H, 2010) |
| "Gemcitabine was administered once a week for 3 weeks followed by a week rest." | 1.36 | [A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy]. ( Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T, 2010) |
| "A 65-year-old man with common bile duct cancer was treated by pylorus-preserving pancreaticoduodenectomy with D2 lymph node dissection." | 1.35 | [A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy]. ( Fukao, K; Irabu, S; Kasagawa, T; Kusashio, K; Matsumoto, M; Nobumoto, D; Suzuki, M; Tashima, Y; Tonooka, T; Udagawa, I; Yasutomi, J, 2008) |
| "Cholangiocarcinoma is a therapeutically challenging malignancy." | 1.35 | Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Wada, H; Yamamoto, Y, 2008) |
| "A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
| "Primary liver cancer with lymph node metastasis was recognized as poor prognosis." | 1.35 | [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. ( Akagi, K; Dono, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kawanishi, K; Kitada, M; Munakata, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yasumoto, T; Zenitani, M, 2009) |
| "A 72-year-old man with common bile duct cancer was treated by pylorus preserving pancreatoduodenectomy with D3 lymph node dissection and preventive radiotherapy at hepaticojejunostomy." | 1.32 | [A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy]. ( Hirano, T; Kitahara, K; Magata, S; Matsuyama, S; Miyazaki, K; Mori, M; Shimonishi, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.13) | 18.7374 |
| 1990's | 2 (3.13) | 18.2507 |
| 2000's | 17 (26.56) | 29.6817 |
| 2010's | 40 (62.50) | 24.3611 |
| 2020's | 3 (4.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, K | 1 |
| Tomimaru, Y | 2 |
| Iwazawa, T | 2 |
| Noguchi, K | 1 |
| Nagase, H | 1 |
| Ogino, T | 1 |
| Hirota, M | 2 |
| Oshima, K | 1 |
| Tanida, T | 2 |
| Noura, S | 1 |
| Kawase, T | 1 |
| Imamura, H | 1 |
| Akagi, K | 3 |
| Dono, K | 3 |
| Liu, J | 1 |
| Wang, C | 1 |
| Cao, L | 1 |
| Li, S | 1 |
| Yang, J | 1 |
| Wang, J | 1 |
| Zhou, H | 1 |
| Wang, Y | 1 |
| Huang, H | 1 |
| Jin, H | 1 |
| Lou, Q | 1 |
| Shah, RJ | 1 |
| Zhang, X | 1 |
| Itano, O | 1 |
| Takemura, Y | 1 |
| Kishida, N | 1 |
| Tamagawa, E | 1 |
| Shinozaki, H | 1 |
| Ikeda, K | 4 |
| Urakami, H | 1 |
| Ei, S | 1 |
| Hayatsu, S | 1 |
| Suzuki, K | 1 |
| Sakuragawa, T | 1 |
| Ishii, M | 1 |
| Shito, M | 1 |
| Aiura, K | 1 |
| Fujisaki, H | 1 |
| Takano, K | 1 |
| Matsui, J | 1 |
| Minagawa, T | 1 |
| Shinoda, M | 1 |
| Kitago, M | 1 |
| Abe, Y | 1 |
| Yagi, H | 1 |
| Oshima, G | 1 |
| Hori, S | 1 |
| Kitagawa, Y | 1 |
| Okabayashi, T | 1 |
| Shima, Y | 1 |
| Iwata, J | 1 |
| Morita, S | 1 |
| Sumiyoshi, T | 1 |
| Sui, K | 1 |
| Shimada, Y | 2 |
| Iiyama, T | 1 |
| Toyota, K | 1 |
| Murakami, Y | 3 |
| Kondo, N | 3 |
| Uemura, K | 3 |
| Nakagawa, N | 3 |
| Takahashi, S | 1 |
| Sueda, T | 3 |
| Abe, K | 2 |
| Uwagawa, T | 1 |
| Haruki, K | 1 |
| Takano, Y | 1 |
| Onda, S | 1 |
| Sakamoto, T | 2 |
| Gocho, T | 1 |
| Yanaga, K | 1 |
| Komiyama, S | 1 |
| Izumiya, Y | 1 |
| Kimura, Y | 1 |
| Nakashima, S | 1 |
| Kin, S | 1 |
| Kawakami, S | 1 |
| Zhang, XZ | 1 |
| Tu, JJ | 1 |
| Chen, W | 2 |
| Ma, T | 1 |
| Bai, XL | 1 |
| Liang, TB | 1 |
| Akahoshi, K | 1 |
| Ban, D | 1 |
| Kuboki, R | 1 |
| Oba, A | 1 |
| Ono, H | 1 |
| Mitsunori, Y | 1 |
| Kudo, A | 1 |
| Tanaka, S | 1 |
| Tanabe, M | 1 |
| Miyata, T | 1 |
| Beppu, T | 2 |
| Imamura, YU | 1 |
| Hayashi, H | 3 |
| Imai, K | 1 |
| Chikamoto, A | 1 |
| Yamashita, YI | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 2 |
| Baba, H | 2 |
| Morino, K | 1 |
| Seo, S | 1 |
| Yoh, T | 1 |
| Nishino, H | 1 |
| Yamanaka, K | 1 |
| Fukumitsu, K | 1 |
| Ishii, T | 1 |
| Taura, K | 1 |
| Okajima, H | 1 |
| Kaido, T | 1 |
| Uemoto, S | 2 |
| Horie, S | 1 |
| Ayaki, M | 1 |
| Kashiwagi, R | 1 |
| Mitsuda, A | 1 |
| Tanaka, H | 2 |
| Sudo, T | 2 |
| Hashimoto, Y | 2 |
| Muto, T | 1 |
| Sasaki, H | 1 |
| Urabe, K | 1 |
| Cai, JP | 1 |
| Hou, X | 1 |
| Liang, LJ | 1 |
| Hao, XY | 1 |
| Yin, XY | 1 |
| Park, DH | 1 |
| Lee, SS | 1 |
| Park, SE | 1 |
| Lee, JL | 1 |
| Choi, JH | 1 |
| Choi, HJ | 1 |
| Jang, JW | 1 |
| Kim, HJ | 1 |
| Eum, JB | 1 |
| Seo, DW | 1 |
| Lee, SK | 1 |
| Kim, MH | 1 |
| Lee, JB | 1 |
| Maeda, T | 1 |
| Hashimoto, K | 1 |
| Ishida, T | 1 |
| Yamashita, Y | 2 |
| Saeki, H | 1 |
| Kawanaka, H | 1 |
| Uchiyama, H | 1 |
| Ikeda, T | 1 |
| Tsujitani, S | 1 |
| Maehara, Y | 1 |
| Iwahashi, S | 1 |
| Utsunomiya, T | 1 |
| Imura, S | 1 |
| Morine, Y | 1 |
| Ikemoto, T | 1 |
| Arakawa, Y | 1 |
| Saito, Y | 1 |
| Ishikawa, D | 1 |
| Shimada, M | 1 |
| Ohkawa, A | 1 |
| Mizumoto, M | 1 |
| Ishikawa, H | 1 |
| Abei, M | 1 |
| Fukuda, K | 1 |
| Hashimoto, T | 1 |
| Sakae, T | 1 |
| Tsuboi, K | 1 |
| Okumura, T | 2 |
| Sakurai, H | 1 |
| Shirasaki, K | 1 |
| Morikawa, T | 2 |
| Otsuka, H | 1 |
| Katayose, Y | 1 |
| Unno, M | 2 |
| Shiozaki, S | 1 |
| Satoh, D | 1 |
| Matsukawa, H | 1 |
| Yamaguchi, K | 1 |
| Takahashi, K | 1 |
| Mimura, N | 1 |
| Taguchi, K | 1 |
| Araki, H | 1 |
| Toshima, T | 1 |
| Kato, T | 1 |
| Miyake, S | 1 |
| Miyoshi, H | 1 |
| Yoshida, K | 1 |
| Choda, Y | 1 |
| Tokumoto, N | 1 |
| Kanazawa, T | 1 |
| Harano, M | 1 |
| Ojima, Y | 1 |
| Idani, H | 1 |
| Okajima, M | 1 |
| Ninomiya, M | 1 |
| Miki, A | 1 |
| Hirose, T | 1 |
| Minami, T | 1 |
| Morioka, H | 1 |
| Suzuki, T | 1 |
| Otani, T | 1 |
| Kitamura, K | 1 |
| Yoshitani, S | 1 |
| Ishikawa, Y | 1 |
| Nishihira, T | 1 |
| Cheong, CO | 1 |
| Lim, JH | 1 |
| Park, JS | 1 |
| Park, SW | 1 |
| Kim, HK | 1 |
| Kim, KS | 1 |
| Kanomata, H | 1 |
| Seyama, Y | 1 |
| Tani, K | 1 |
| Tanizawa, T | 1 |
| Warabi, M | 1 |
| Murayama, M | 1 |
| Asano, T | 1 |
| Takahashi, M | 1 |
| Matsuoka, Y | 1 |
| Miyamoto, Y | 1 |
| Umekita, N | 1 |
| Aoki, S | 1 |
| Mizuma, M | 1 |
| Oyauchi, M | 1 |
| Yoshida, H | 1 |
| Okada, R | 1 |
| Abe, T | 2 |
| Sakata, N | 1 |
| Nakagawa, K | 1 |
| Motoi, F | 1 |
| Naitoh, T | 1 |
| Okada, Y | 1 |
| Yamamichi, K | 1 |
| Sueyoshi, H | 1 |
| Tanaka, Y | 1 |
| Sakaguchi, T | 1 |
| Hishikawa, H | 1 |
| Ueda, A | 1 |
| Matsuura, T | 1 |
| Ozaki, T | 1 |
| Saito, T | 1 |
| Fushimi, K | 1 |
| Omori, T | 1 |
| Nishimura, M | 1 |
| Kawada, J | 1 |
| Matsuura, N | 1 |
| Kitagawa, A | 1 |
| Nomura, M | 1 |
| Okumura, Y | 1 |
| Nakatsuka, R | 1 |
| Miyazaki, S | 1 |
| Danno, K | 1 |
| Motoori, M | 1 |
| Kubota, M | 1 |
| Matsuda, C | 1 |
| Fujitani, K | 1 |
| Iwase, K | 1 |
| Li, H | 2 |
| Zhang, Z | 1 |
| Zhou, Z | 1 |
| Ding, X | 1 |
| Zhou, G | 1 |
| Zhang, ZY | 1 |
| Zhou, ZQ | 1 |
| Guan, J | 1 |
| Tong, DN | 1 |
| Zhou, GW | 1 |
| Kuga, Y | 1 |
| Moriya, T | 1 |
| Fukuda, S | 1 |
| Nishida, T | 1 |
| Nishiguchi, R | 1 |
| Kim, DH | 1 |
| Honda, M | 1 |
| Miyamoto, A | 1 |
| Hama, N | 1 |
| Maeda, S | 1 |
| Uemura, M | 1 |
| Yamamoto, K | 1 |
| Miyake, K | 1 |
| Nishikawa, K | 1 |
| Miyazaki, M | 1 |
| Ikeda, M | 3 |
| Hirao, M | 1 |
| Sekimoto, M | 1 |
| Nakamori, S | 1 |
| Matsumoto, M | 1 |
| Udagawa, I | 1 |
| Yasutomi, J | 1 |
| Kusashio, K | 1 |
| Kasagawa, T | 1 |
| Tonooka, T | 1 |
| Tashima, Y | 1 |
| Irabu, S | 1 |
| Nobumoto, D | 1 |
| Suzuki, M | 2 |
| Fukao, K | 1 |
| Morinaga, S | 1 |
| Yamamoto, Y | 1 |
| Sugano, N | 1 |
| Wada, H | 2 |
| Shiozawa, M | 1 |
| Akaike, M | 1 |
| Sugimasa, Y | 1 |
| Furuse, J | 2 |
| Okusaka, T | 2 |
| Ohkawa, S | 1 |
| Nagase, M | 2 |
| Funakoshi, A | 2 |
| Boku, N | 1 |
| Yamao, K | 2 |
| Yamaguchi, T | 1 |
| Sato, T | 1 |
| Kanaji, S | 1 |
| Kobayashi, I | 1 |
| Fujita, T | 1 |
| Ueno, K | 1 |
| Tsuchida, S | 1 |
| Kawasaki, K | 1 |
| Ohno, M | 1 |
| Osawa, M | 1 |
| Fujino, Y | 1 |
| Tominaga, M | 1 |
| Nakamura, T | 1 |
| Wakatsuki, T | 1 |
| Katsushima, F | 1 |
| Monoe, K | 1 |
| Kanno, Y | 1 |
| Takahashi, A | 1 |
| Yokokawa, J | 1 |
| Ohira, H | 1 |
| Yamada, M | 1 |
| Shiroeda, H | 1 |
| Shiroeda, S | 1 |
| Sato, K | 1 |
| Arisawa, T | 1 |
| Tsutsumi, M | 1 |
| Kadono, K | 1 |
| Kawamoto, K | 1 |
| Park, T | 1 |
| Hatano, H | 1 |
| Kobayashi, S | 2 |
| Nagano, H | 2 |
| Tomokuni, A | 1 |
| Murakami, M | 1 |
| Marubashi, S | 2 |
| Eguchi, H | 2 |
| Takeda, Y | 2 |
| Tanemura, M | 2 |
| Wakasa, K | 1 |
| Doki, Y | 2 |
| Mori, M | 3 |
| Shimizu, J | 2 |
| Hayashi, S | 1 |
| Yasumoto, T | 1 |
| Zenitani, M | 1 |
| Munakata, K | 1 |
| Watanabe, N | 1 |
| Takamoto, K | 1 |
| Kagawa, Y | 1 |
| Hata, T | 2 |
| Kawanishi, K | 2 |
| Fujita, J | 2 |
| Kitada, M | 2 |
| Shimano, T | 2 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Nakagawa, T | 1 |
| Nakanishi, K | 1 |
| Tahara, M | 1 |
| Fukumori, D | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Akiyama, N | 1 |
| Ayata, S | 1 |
| Maruyama, Y | 1 |
| Tsukada, Y | 1 |
| Umeshita, H | 1 |
| Tamura, T | 1 |
| Mizuyama, Y | 1 |
| Shinto, O | 1 |
| Nishihara, T | 1 |
| Nakagawa, H | 1 |
| Ono, Y | 1 |
| Kamo, N | 1 |
| Mori, A | 1 |
| Nitta, T | 1 |
| Hatano, E | 1 |
| Mitsuyoshi, H | 1 |
| Makino, H | 1 |
| Kametaka, H | 1 |
| Koyama, T | 1 |
| Seike, K | 1 |
| Nagai, K | 1 |
| Miyake, M | 1 |
| Suzuki, S | 1 |
| Morishita, K | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Takeo, Y | 1 |
| Harada, N | 1 |
| Hayashi, T | 1 |
| Imaizumi, T | 1 |
| Nakashima, A | 1 |
| Sakabe, R | 1 |
| Kobayashi, H | 1 |
| Sekine, S | 1 |
| Nagata, T | 1 |
| Moriyama, M | 1 |
| Omura, T | 1 |
| Watanabe, T | 1 |
| Hori, R | 1 |
| Yoshioka, I | 1 |
| Sawada, S | 1 |
| Fukuoka, J | 1 |
| Tsukada, K | 1 |
| Tada, S | 1 |
| Fujikawa, T | 1 |
| Tanaka, A | 1 |
| Yoshimoto, Y | 1 |
| Maekawa, H | 1 |
| Shimoike, N | 1 |
| Kawashima, T | 1 |
| Shiraishi, K | 1 |
| Matsuyama, S | 1 |
| Kitahara, K | 1 |
| Hirano, T | 1 |
| Magata, S | 1 |
| Shimonishi, T | 1 |
| Miyazaki, K | 1 |
| Ishii, H | 1 |
| Nakachi, K | 1 |
| Ueno, H | 2 |
| Morizane, C | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Masuda, T | 1 |
| Mizumoto, T | 1 |
| Hosaka, S | 1 |
| Nakahara, O | 1 |
| Okabe, H | 1 |
| Yamanaka, T | 1 |
| Okabe, K | 1 |
| Takamori, H | 1 |
| Kanemitsu, K | 1 |
| Hanada, N | 1 |
| Kusano, S | 1 |
| Hori, K | 1 |
| Momi, H | 1 |
| Mori, Y | 1 |
| Katsumata, K | 1 |
| Tokita, H | 1 |
| Kato, F | 1 |
| Yamamoto, J | 1 |
| Tsuchida, A | 1 |
| Aoki, T | 1 |
| Guan, YS | 1 |
| Fu, YC | 1 |
| Zhao, SW | 1 |
| Yamamoto, S | 1 |
| Hirata, T | 1 |
| Yamagishi, S | 1 |
| Hirano, S | 1 |
| Kutsukata, N | 1 |
| Masuda, S | 1 |
| Hisayoshi, T | 1 |
| Hioki, M | 1 |
| Mani, S | 1 |
| Sciortino, D | 1 |
| Samuels, B | 1 |
| Arrietta, R | 1 |
| Schilsky, RL | 1 |
| Vokes, EE | 1 |
| Benner, S | 1 |
| Uehara, S | 1 |
| Hirano, F | 1 |
| Sakai, N | 1 |
| Honjo, K | 1 |
| Hirayama, A | 1 |
| Moriya, H | 1 |
| Sakata, Y | 1 |
| Fukushi, G | 1 |
| Tsushima, K | 1 |
| Suzuki, H | 1 |
| Kimura, T | 1 |
| Kimura, M | 1 |
| Tamura, Y | 1 |
| Kishibe, T | 1 |
| Saitoh, S | 1 |
| Itoh, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control[NCT02592538] | 66 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698] | Phase 2 | 62 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | ||
| Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control[NCT00869635] | Phase 3 | 43 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for tegafur and Bile Duct Neoplasms
| Article | Year |
|---|---|
[A Distal Bile Duct Carcinoma Patient Who Underwent Surgical Resection for Liver Metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2018 |
9 trials available for tegafur and Bile Duct Neoplasms
| Article | Year |
|---|---|
Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrah | 2020 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2018 |
Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neopla | 2014 |
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Drug C | 2014 |
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; D | 2016 |
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Du | 2009 |
[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Female; Gallbladder Neopl | 1999 |
54 other studies available for tegafur and Bile Duct Neoplasms
| Article | Year |
|---|---|
[A Case with Three Resections of the Pulmonary Metastases of a Distal Bile Duct Carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Drug Combinations; Humans; L | 2019 |
Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2020 |
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Carcino | 2020 |
Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2017 |
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell N | 2018 |
Gallbladder cancer with tumor thrombus in the portal vein: A case report.
Topics: Administration, Intravenous; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; D | 2018 |
Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Chemot | 2019 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Pr | 2019 |
[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Deoxycytidin | 2013 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Cultur | 2013 |
Repeat hepatectomy for intrahepatic recurrence of cholangiolocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2013 |
Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
[A long term survival case of hilar cholangiocarcinoma with multiple metastases treated with chemotherapy and operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cathe | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 2014 |
[Six-year survival with recurrent intrahepatic cholangiocarcinoma achieved by simple S-1 administration].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 2015 |
Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Embolization, Therapeutic; Gam | 2015 |
[Long Term Survival in a Case of Hilar Cholangiocarcinoma Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deo | 2015 |
[A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidi | 2015 |
[A Case of Local Recurrence of Bile Duct Cancer Completely Responding to Chemoradiotherapy with S-1].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Drug Com | 2015 |
[A Three-Year Survival Case of Extrahepatic Cholangiocarcinoma Treated with Palliative Bile Duct Resection and S-1 Monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarci | 2015 |
[A Case of Resected Gastric Cancer Occurring Simultaneously with Intrahepatic Cholangiocarcinoma after S-1 plus Cisplatin Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocar | 2015 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Chol | 2016 |
[Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxy | 2016 |
Squamous cell carcinoma of the extrahepatic bile duct with metachronous para-aortic lymph node metastasis successfully treated with S-1 plus cisplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Squ | 2016 |
[A Case of Lymph Node Metastasis of Intrahepatic Bile Duct Cancer Successfully Treated Using Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2016 |
[A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Drug C | 2008 |
Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2008 |
[A case of curatively resected biliary tract cancer with peritoneal dissemination through effective response to chemotherapy of S-1].
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholecystectomy; Female; Hepatectomy; Humans; Middle | 2009 |
A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2009 |
Cholangiocarcinoma producing parathyroid hormone-related peptide treated with chemoradiation using gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2009 |
[A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Drug Combinations; Humans; | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2009 |
[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Combination | 2010 |
[A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, | 2010 |
[Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2011 |
[A case of long-term survival of a patient with intrahepatic bile duct cancer and early nodal recurrence who responded to S-1 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Drug Combinati | 2011 |
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; | 2011 |
[A case of bile duct cancer with positive surgical margin obtaining long-term survival after S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Combined Modality Therapy; Drug Combinat | 2012 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2012 |
Prognostic significance of aquaporins in human biliary tract carcinoma.
Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Bio | 2012 |
[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2012 |
[A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Common Bile Duct; Drug Administrat | 2004 |
[A long term survival case of advanced intrahepatic cholangiocarcinoma treated with multidisciplinary treatment].
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone Neoplasms; Catheter Ablation; Chemoembolization, | 2006 |
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2007 |
[Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Drug | 2007 |
[A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
Arterial chemotherapy and conformal radiation abolish malignant biliary obstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2008 |
[A case of far-advanced gastric cancer treated with neoadjuvant combination chemotherapy of UFT, low-dose CDDP and leucovorin, followed by subtotal gastrectomy with curative intent].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 1997 |
[A case of cholangiocarcinoma with marked reduction of tumor after oral administration of UFT].
Topics: Adenoma, Bile Duct; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile Duct | 1989 |
[MQF-FT and MQF-UFT in gallbladder and bile duct cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Car | 1988 |